JP2017534577A - Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 - Google Patents

Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 Download PDF

Info

Publication number
JP2017534577A
JP2017534577A JP2017514474A JP2017514474A JP2017534577A JP 2017534577 A JP2017534577 A JP 2017534577A JP 2017514474 A JP2017514474 A JP 2017514474A JP 2017514474 A JP2017514474 A JP 2017514474A JP 2017534577 A JP2017534577 A JP 2017534577A
Authority
JP
Japan
Prior art keywords
binding antagonist
expression
antibody
seq
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2017514474A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017534577A5 (enExample
Inventor
ジェーン グローガン，
ジェーン グローガン，
ユアンユアン シアオ，
ユアンユアン シアオ，
パトリック カプラツィー，
パトリック カプラツィー，
スティーヴ リャノグロウ，
スティーヴ リャノグロウ，
ジェイソン ハックニー，
ジェイソン ハックニー，
ユージーン ユイ−チョアン チャン，
ユージーン ユイ−チョアン チャン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2017534577A publication Critical patent/JP2017534577A/ja
Publication of JP2017534577A5 publication Critical patent/JP2017534577A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2017514474A 2014-09-15 2015-09-14 Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法 Withdrawn JP2017534577A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462050745P 2014-09-15 2014-09-15
US62/050,745 2014-09-15
PCT/US2015/050051 WO2016044189A1 (en) 2014-09-15 2015-09-14 Methods of treating cancer using pd-1 axis binding antagonist and il-17 binding antagonists

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020143036A Division JP2021001176A (ja) 2014-09-15 2020-08-26 Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法

Publications (2)

Publication Number Publication Date
JP2017534577A true JP2017534577A (ja) 2017-11-24
JP2017534577A5 JP2017534577A5 (enExample) 2018-10-25

Family

ID=54325043

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017514474A Withdrawn JP2017534577A (ja) 2014-09-15 2015-09-14 Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法
JP2020143036A Pending JP2021001176A (ja) 2014-09-15 2020-08-26 Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020143036A Pending JP2021001176A (ja) 2014-09-15 2020-08-26 Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法

Country Status (5)

Country Link
US (3) US20170274073A1 (enExample)
EP (1) EP3194440A1 (enExample)
JP (2) JP2017534577A (enExample)
CN (1) CN106687135A (enExample)
WO (1) WO2016044189A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020218322A1 (ja) * 2019-04-23 2020-10-29 国立大学法人東北大学 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果予測
JP2022527345A (ja) * 2019-04-03 2022-06-01 オレガ・バイオテック Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
JP2023525234A (ja) * 2020-04-30 2023-06-15 ヤンセン ファーマシューティカ エヌ．ベー． Ｉｌ－１７経路のモジュレータを同定する方法

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
BR112018011029A2 (pt) 2016-01-08 2018-11-21 Hoffmann La Roche métodos para tratar ou atrasar a progressão do câncer e para melhorar a função imune em um indivíduo com câncer, usos de um antagonista de ligação e de um anticorpo biespecífico, composições e kits
US20190033322A1 (en) * 2016-02-03 2019-01-31 The Cleveland Clinic Foundation Detection and treatment of il-17 and il-13 related conditions
EP3440219B1 (en) * 2016-04-08 2021-09-01 Centre National De La Recherche Scientifique Methods and kits for predicting the sensitivity of a subject suffering of renal cancer to cancer treatment
WO2018027524A1 (en) * 2016-08-09 2018-02-15 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibody formulation
WO2018075740A1 (en) * 2016-10-21 2018-04-26 Merck Sharp & Dohme Corp. Treating cancer with a combination of pd-1 antagonist and an il-27 antagonist
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
CN110546509A (zh) 2017-04-28 2019-12-06 戊瑞治疗有限公司 用cd80细胞外结构域多肽进行治疗的方法
US11220550B2 (en) * 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
WO2018236728A1 (en) 2017-06-18 2018-12-27 Kindred Biosciences, Inc. ANTIBODIES AND ANTAGONISTS OF IL17A FOR VETERINARY USE
AU2018318440A1 (en) 2017-08-15 2020-02-13 Kindred Biosciences, Inc. IgG Fc variants for veterinary use
EP3483180A1 (en) * 2017-11-14 2019-05-15 Affilogic Multi specific molecules
WO2019140150A1 (en) * 2018-01-12 2019-07-18 Bristol-Myers Squibb Company Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
WO2019152344A1 (en) * 2018-01-30 2019-08-08 University Of Louisville Research Foundation, Inc. Compositions and methods for treating inflammation and cancer
US20210363590A1 (en) * 2018-05-21 2021-11-25 Nanostring Technologies, Inc. Molecular gene signatures and methods of using same
CN110563842B (zh) * 2018-06-06 2022-07-29 浙江博锐生物制药有限公司 针对程序性死亡配体(pd-l1)的抗体及其应用
KR102091637B1 (ko) * 2018-07-10 2020-03-20 연세대학교 산학협력단 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트
CN109053891B (zh) 2018-09-17 2021-12-21 苏州泓迅生物科技股份有限公司 一种抗pd-l1抗体及其制备方法和应用
WO2020150208A1 (en) * 2019-01-14 2020-07-23 Board Of Regents, The University Of Texas System Compositions and methods for treating cancer using il-17 signaling inhibitors and immune checkpoint inhibitors
AU2020224137B2 (en) 2019-02-22 2026-01-08 Five Prime Therapeutics, Inc. CD80 extracellular domain-Fc fusion proteins for treating PD-L1 negative tumors
MX2021013272A (es) 2019-05-03 2021-11-17 Five Prime Therapeutics Inc Formulaciones farmaceuticas que contienen proteinas de fusion fc de dominio extracelular de cd80.
CN115698717A (zh) * 2020-04-03 2023-02-03 基因泰克公司 癌症的治疗和诊断方法
US20240400668A1 (en) * 2022-07-29 2024-12-05 Jinfeng Laboratory Non-human mammalian model expressing il-8 and use thereof
EP4735889A1 (en) * 2023-06-30 2026-05-06 Universität Duisburg-Essen Il-17 based therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141823A2 (en) * 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2013019906A1 (en) * 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201018482A (en) * 2008-08-08 2010-05-16 Glaxo Wellcome Mfg Pte Ltd Novel treatment
JP2014525412A (ja) * 2011-08-17 2014-09-29 ジェネンテック， インコーポレイテッド 難治性腫瘍における血管新生の阻害
KR101463325B1 (ko) * 2013-01-14 2014-11-20 가톨릭대학교 산학협력단 HtrA2 단백질을 유효성분으로 포함하는 자가면역질환의 예방 또는 치료용 조성물

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011141823A2 (en) * 2010-05-14 2011-11-17 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
WO2013019906A1 (en) * 2011-08-01 2013-02-07 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CANCER LETTERS, 2013, VOL.336, P.253-259, JPN6019032971, ISSN: 0004102897 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022527345A (ja) * 2019-04-03 2022-06-01 オレガ・バイオテック Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
JP2025123237A (ja) * 2019-04-03 2025-08-22 オレガ・バイオテック Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
JP7795737B2 (ja) 2019-04-03 2026-01-08 オレガ・バイオテック Ｐｄ１阻害剤及びｉｌ－１７ｂ阻害剤に基づく複合療法
WO2020218322A1 (ja) * 2019-04-23 2020-10-29 国立大学法人東北大学 血中ケモカインを用いた免疫チェックポイント阻害薬の治療効果予測
JP2023525234A (ja) * 2020-04-30 2023-06-15 ヤンセン ファーマシューティカ エヌ．ベー． Ｉｌ－１７経路のモジュレータを同定する方法

Also Published As

Publication number Publication date
US20170274073A1 (en) 2017-09-28
JP2021001176A (ja) 2021-01-07
WO2016044189A1 (en) 2016-03-24
WO2016044189A9 (en) 2017-05-11
WO2016044189A8 (en) 2017-03-23
US20200155676A1 (en) 2020-05-21
EP3194440A1 (en) 2017-07-26
US20200405855A1 (en) 2020-12-31
CN106687135A (zh) 2017-05-17

Similar Documents

Publication Publication Date Title
JP2021001176A (ja) Ｐｄ−１軸結合拮抗薬及びｉｌ−１７結合拮抗薬を使用したがんの治療方法
CN111213059B (zh) 用于癌症的诊断和治疗方法
KR102500659B1 (ko) 암에 대한 치료 및 진단 방법
JP6312659B2 (ja) Ｐｄ−１系結合アンタゴニスト及びｖｅｇｆアンタゴニストを用いた癌の治療方法
JP2021061838A (ja) Ｏｘ４０アゴニスト治療薬の有効性及び評価を予測するための方法及びバイオマーカー
CN106796235B (zh) 用于检测t细胞免疫子集的测定法及其使用方法
JP2017537090A (ja) Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
JP2019535237A (ja) がんのための治療方法及び診断方法
JP2019521641A (ja) がんを監視及び治療するための方法
KR20180012753A (ko) 암에 대한 치료 및 진단 방법
JP2017501167A (ja) Ｏｘ４０結合アゴニスト及びｐｄ−１軸結合アンタゴニストを含む併用療法
JP2018518483A (ja) 抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
KR20160030936A (ko) Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
HK1250376A1 (zh) 用於癌症的治疗和诊断方法
KR20180066236A (ko) Icos 발현을 계측하기 위한 유전자 특질
KR20190003957A (ko) 암 모니터링 및 치료 방법
JP2023536602A (ja) リンパ腫のための診断及び治療方法
CN114269376A (zh) 用抗pd-l1抗体治疗癌症的方法
KR20230024368A (ko) 항-tigit 항체 및 pd-1 축 결합 길항제를 사용한 치료
JP7475336B2 (ja) トリプルネガティブ乳癌のための診断方法
KR20220070237A (ko) 항-tigit 및 항-pd-l1 길항제 항체를 이용한 치료를 위한 투약
JP2023520515A (ja) がんに対する治療方法及び診断方法
KR20230025691A (ko) 삼중 음성 유방암을 치료하기 위한 방법과 조성물
JP2023523450A (ja) 非小細胞肺がん免疫療法のための方法及び組成物
HK1237659A1 (en) Methods of treating cancer using pd-1 axis binding antagonists and il-17 binding antagonists

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180914

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180914

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190827

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191118

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200123

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200826

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20200828